Alto Neuroscience, Inc. (ANRO) vs Replimune Group, Inc. (REPL)

Alto Neuroscience, Inc. and Replimune Group, Inc. are both Biotechnology companies. Replimune Group, Inc. is the larger, with a market value of $1.2B against $1.1B — 1.1× the size. Across the 10 metrics below, Alto Neuroscience, Inc. leads on 9 and Replimune Group, Inc. on 1.

Valuation

Metric ANRO REPL Biotechnology median
P/E n/m n/m 7.88
P/S n/m n/m 11.47
P/B 5.17 11.37 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m n/m 10.73
Earnings yield (9.14%) (25.40%) (28.84%)
Free cash flow yield (6.07%) (23.36%) (23.03%)

Profitability

Metric ANRO REPL Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (49.17%) (134.29%) (57.72%)
Return on assets (40.90%) (82.28%) (49.22%)
Return on invested capital 0.00% (1,154.69%) 0.00%

Growth

Metric ANRO REPL Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 12.40% (10.10%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ANRO REPL Biotechnology median
Debt to equity 0.09 1.00 0.00
Current ratio 14.85 5.23 4.73
Net debt to EBITDA 2.40 0.51 0.96

Dividend

Metric ANRO REPL Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric ANRO REPL Biotechnology median
Market cap 1.07b 1.20b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack